Belantamab Mafodotin Mechanism of Action: Explaining Induction of Immunogenic & Inflammatory Cell Death to Remodel the Tumour Microenvironment in Patients
- Highlighting the importance of in-depth translational characterisation of late-stage ADC assets to understand clinical success
- Explaining how belantamab Mafodotin mechanism of action enables durable patient responses in the clinic
- Laying out lessons learnt that can influence how subsequent and future ADCs are designed